Oncology drug developer Olema Pharmaceuticals' Q4 net loss widens on higher R&D costs
Overview
US breast cancer drug developer's Q4 net loss widened on higher R&D expenses
Company ended 2025 with $505.4 mln in cash and equivalents after $218.5 mln public offering
Increased R&D spending driven by late-stage trials for palazestrant and advancement of OP-3136
Result Drivers
CLINICAL TRIAL ADVANCEMENT - Increased R&D expenses attributed to late-stage trials for palazestrant and development of OP-3136
INCREASED CORPORATE COSTS - Higher G&A expenses due to increased spending on corporate-related costs
Company press release: ID:nGNX9FCg4N
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Income |
| -$46.06 mln |
|
Q4 Income From Operations |
| -$50.08 mln |
|
Q4 Operating Expenses |
| $50.08 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Olema Pharmaceuticals Inc is $43.00, about 192.3% above its March 13 closing price of $14.71
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
